By Kristen Hallam - Mar 8, 2011 7:27 AM ET
Gilead Sciences Inc. (GILD)’s four-drug combination eliminated hepatitis C virus in patients in an early-stage study, RBC Capital Markets LLC analysts said.
The findings support an ongoing mid-stage study of the combination, the analysts, led by Michael Yee in San Francisco, wrote yesterday in a note to investors, citing an abstract of the trial. The analysts said they expect data next year from a mid-stage study by the Foster City, California-based company.
The early-stage study examined a combination of Gilead’s GS-9256 and GS-9190 with two older drugs that are the standard of care, ribavirin and Peg-interferon, according to the note.
The data will be presented at the annual meeting of the European Association for the Study of the Liver starting March 30 in Berlin.
To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net
Source
No comments:
Post a Comment